Salud financiera de hoja de balance de Clinuvel Pharmaceuticals
Salud financiera controles de criterios 6/6
Clinuvel Pharmaceuticals tiene un patrimonio de accionistas total de A$178.7M y una deuda total de A$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son A$211.7M y A$33.0M respectivamente. El BAIT de Clinuvel Pharmaceuticals es de A$43.8M, por lo que su ratio de cobertura de intereses es de -19.1. Tiene efectivo e inversiones a corto plazo que ascienden a A$174.4M.
Información clave
0%
Ratio deuda-patrimonio
AU$0
Deuda
| Ratio de cobertura de intereses | -19.1x |
| Efectivo | AU$174.45m |
| Patrimonio | AU$178.65m |
| Total pasivo | AU$33.03m |
| Activos totales | AU$211.68m |
Actualizaciones recientes sobre salud financiera
No hay actualizaciones
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (A$201.5M) de CUV superan a sus pasivos a corto plazo (A$29.4M).
Pasivo a largo plazo: Los activos a corto plazo de CUV (A$201.5M) superan a sus pasivos a largo plazo (A$3.6M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: CUV está libre de deudas.
Reducción de la deuda: CUV no ha tenido ninguna deuda en los últimos 5 años.
Cobertura de la deuda: CUV no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.
Cobertura de intereses: CUV no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.